*SILIQ stops the action of a family of 4 proteins involved in psoriasis by blocking the gateway through which these proteins work. Other biologic medicines that work against this family of proteins target one protein from this group and have no effect on the other 3 proteins.7-9

See the SILIQ
difference in action

First and only IL-17
Receptor blocker

SILIQ blocks IL-17A, IL-17C, IL-17E (IL-25) and IL-17F via their receptor to stop the proinflammatory cascade that leads to psoriasis.7

  • Blocking IL-17 Receptor A inhibits IL-17 cytokine-induced responses7

The clinical significance of these characteristics is not fully known.

IL-17 Cytokines
in Psoriasis10-12

IL-17 cytokines are key players in
the development of psoriasis.10-12

Cytokine In Psoriasis Blocked by Receptor Complex
IL-17A Elevated 28x13 SILIQ7 IL-17RA/RC12
IL-17C Elevated 30x13 SILIQ7 IL-17RA/RE12
IL-17E (IL-25) Elevated11 SILIQ7 IL-17RA/RB14
IL-17F Elevated 33x13 SILIQ7 IL-17RA/RC12
IL-17A/F Elevated12 SILIQ7 IL-17RA/RC12
Cytokine IL-17A IL-17C IL-17E (IL-25) IL-17F IL-17A/F In Psoriasis Elevated 28x13 Elevated 30x13 Elevated11 Elevated 33x13 Elevated12 Blocked by SILIQ7 SILIQ7 SILIQ7 SILIQ7 SILIQ7 ReceptorComplex IL-17RA/RC12 IL-17RA/RE12 IL-17RA/RB14 IL-17RA/RC12 IL-17RA/RC12

IL-17A inhibitors impede IL-17A.8,9 SILIQ blocks all of these IL-17 cytokines because it blocks interactions with the receptor that binds them: IL-17RA.7

A recent article establishes the role of IL-17C as critical in the development of psoriasis and characterizes it as the most abundant IL-17 cytokine in psoriatic lesional skin.15

IL-17 Receptor complexes12,14

Dosing

3 injections to start, followed by 1 injection every other week7

 

Start

Week 1

Week 2

SILIQ should be taken
once a week for
3 weeks.

Week 3

Week 4

Week 5

Week 6

...

After that, SILIQ should be taken once every 2 weeks. Remind your patients that consistent dosing leads to consistent results

IMPORTANT ADMINISTRATION INFORMATION
  • No step down dosing
  • Dosed as a single 210-mg injection weekly for the first 3 weeks and every 2 weeks thereafter.7
  • SILIQ is supplied as a carton of two 1.5 mL (210 mg dose) pre-filled syringes.7
  • Do not inject SILIQ into area where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
  • If an adequate response to SILIQ has not been achieved within 12 to 16 weeks, consider discontinuing therapy. Continued treatment beyond 16 weeks in patients who have not achieved an adequate response is not likely to result in greater success.
  • SILIQ is a subcutaneous injection intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SILIQ when deemed appropriate by a healthcare professional and after training and subcutaneous injection technique using the pre-filled syringe. Patients should be instructed to review the Medication Guide and Instructions for Use before initiating treatment.
woman sitting comfortably in chair, looking happy

SILIQ success stories

See how SILIQ could save their day — even if the day is just spent relaxing at the pool with their kids.

graphic icon of piggy bank

SILIQ Savings

Learn how we’re helping more patients go for total clearance.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
portrait of male doctor looking confident

Get SILIQ certified

It’s simple. Enrolling in our REMS program takes just a few minutes.

portrait of male doctor looking confident

Important Safety Information for SILIQ (brodalumab) Injection

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].

Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].

Crohn’s Disease

SILIQ is contraindicated in patients with Crohn’s disease. In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease.

SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program

SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com

Infections

SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

  • Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection
  • Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur

Risk for Latent Tuberculosis (TB) Reactivation

Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.

Immunizations

Avoid use of live vaccines in patients treated with SILIQ.

Adverse Reactions

The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

To report SUSPECTED ADVERSE REACTIONS, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.

Please click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.

Indication
Indication and Important Safety Information

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

WARNING: SUICIDAL IDEATION AND BEHAVIOR

Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health

Important Safety Information for SILIQ (brodalumab) Injection

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].

Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].

Crohn’s Disease

SILIQ is contraindicated in patients with Crohn’s disease. In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease.

SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program

SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com

Infections

SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

  • Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection
  • Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur

Risk for Latent Tuberculosis (TB) Reactivation

Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.

Immunizations

Avoid use of live vaccines in patients treated with SILIQ.

Adverse Reactions

The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

To report SUSPECTED ADVERSE REACTIONS, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.

Please click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.